The high level of CCL18 in patients with fibrotic lung diseases is indicative of pulmonary fibrotic activity [95] and is a potential biomarker for IPF [96] and for the early identification of progressive ILD [97]. Here, CCL18 is linked to idiopathic interstitial pneumonia.